GRβ Regulates Glucocorticoid Resistance in Sudden Sensorineural Hearing Loss

Page: [1206 - 1215] Pages: 10

  • * (Excluding Mailing and Handling)

Abstract

Background: In recent years, the incidence of sudden deafness has gradually increased, with a very limited understanding of its etiology and pathogenesis. Glucocorticoids are the first choice of the treatment, but some hormone-resistant patients are not sensitive to glucocorticoid therapy. The pathogenesis is not yet known. In this study, we aim to construct the HEI-OC1 cell line stably overexpressing Glucocorticoid Receptor Beta (GRβ), and identify its exact role in the cases of glucocorticoidresistant sudden deafness.

Methods: We used the endotoxin lipopolysaccharide-stimulated cochlear hair cells (HEI-OC1) to investigate the relationship of inflammation factor IL-2, TNF alpha, and SRp30c with the high expression GRβ. We built a stable GRβ high expression HEI-OC1 cell line and clarified its effects on the therapeutic effect of dexamethasone. MTT assay, colony formation assay, CCK-8 assay, Western blot, and RT-qPCR were utilized for characterizations.

Results: Dexamethasone reduced the LPS-induced inflammatory response from HEI-OC1 cells (p<0.05), detected by MTT assay. Dexamethasone could protect HEI-OC1 cells, but its protective effect was weakened due to the transfection of SRp30c over-expression plasmid (p<0.05). The transfection of SRp30c over-expression plasmid in HEI-OC1 cells could elevate the expressions of GRβ (p<0.05).

Conclusion: We clarified the mechanisms of high expression of GRβ in glucocorticoid-resistant sudden sensorineural hearing loss, and proved that the inhibition of SRp30c may act as a new treatment way of glucocorticoid-resistant sudden sensorineural hearing loss.

Keywords: Glucocorticoid resistance, dexamethasone, sudden sensorineural hearing loss, GRβ, SRp30c, LPS.

Graphical Abstract

[1]
Staecker, H.; Jokovic, G.; Karpishchenko, S.; Kienle-Gogolok, A.; Krzyzaniak, A.; Lin, C-D.; Navratil, P.; Tzvetkov, V.; Wright, N.; Meyer, T. Efficacy and safety of AM-111 in the treatment of acute unilateral sudden deafness-a double-blind, randomized, placebo-controlled phase 3 study. Otol. Neurotol., 2019, 40(5), 584-594.
[http://dx.doi.org/10.1097/MAO.0000000000002229] [PMID: 31083077]
[2]
Capuano, L.; Cavaliere, M.; Lopardo, D.; Parente, G.; Damiano, A.; Perone, R.; Marino, A.; Bottiglieri, P.; Iemma, M. Right-to-left shunt and idiopathic sudden sensorineural hearing loss. Acta Otorhinolaryngol. Ital., 2019, 39(2), 103-106.
[http://dx.doi.org/10.14639/0392-100X-1796] [PMID: 31097828]
[3]
Attanasio, G.; Russo, F.Y.; Di Porto, E.; Cagnoni, L.; Masci, E.; Ralli, M.; Greco, A.; De Vincentiis, M. Prediction of hearing recovery in sudden deafness treated with intratympanic steroids. Acta Otorhinolaryngol. Ital., 2018, 38(5), 453-459.
[PMID: 30498274]
[4]
Okuda, T.; Takaki, M.; Hayashi, T.; Hanamure, Y. A case of aggravation of hearing loss during steroid and hyperbaric oxygen therapy for sudden deafness in a patient with diabetes mellitus. Practica otorhino-laryngologica. Suppl., 2017, 151, 2-3.
[5]
Bravenboer de Sousa, M.; Cazemier, S.; Stegeman, I.; Thomeer, H. Use of vasodilators in idiopathic sudden sensorineural hearing loss: A systematic review. J. Int. Adv. Otol., 2017, 13(3), 399-403.
[http://dx.doi.org/10.5152/iao.2017.2966] [PMID: 29283102]
[6]
Fusconi, M.; Chistolini, A.; Angelosanto, N.; Pignoloni, P.; Tombolini, M.; De Virgilio, A.; Pagliarella, M.; de Vincentiis, M. Role of genetic and acquired prothrombotic risk factors in genesis of sudden sensorineural hearing loss. Audiol. Neurotol., 2011, 16(3), 185-190.
[http://dx.doi.org/10.1159/000319310] [PMID: 20798492]
[7]
Janecke, A.R.; Hirst-Stadlmann, A.; Günther, B.; Utermann, B.; Müller, T.; Löffler, J.; Utermann, G.; Nekahm-Heis, D. Progressive hearing loss, and recurrent sudden sensorineural hearing loss associated with GJB2 mutations-phenotypic spectrum and frequencies of GJB2 mutations in Austria. Hum. Genet., 2002, 111(2), 145-153.
[http://dx.doi.org/10.1007/s00439-002-0762-y] [PMID: 12189487]
[8]
Merchant, S.N.; Durand, M.L.; Adams, J.C. Sudden deafness: Is it viral? ORL J. Otorhinolaryngol. Relat. Spec., 2008, 70(1), 52-60.
[http://dx.doi.org/10.1159/000111048] [PMID: 18235206]
[9]
Gundogan, O.; Pinar, E.; Imre, A.; Ozturkcan, S.; Cokmez, O.; Yigiter, A.C. Therapeutic efficacy of the combination of intratympanic methylprednisolone and oral steroid for idiopathic sudden deafness. Otolaryngol. Head Neck Surg., 2013, 149(5), 753-758.
[http://dx.doi.org/10.1177/0194599813500754] [PMID: 23959817]
[10]
Mort, D.J.; Bronstein, A.M. Sudden deafness. Curr. Opin. Neurol., 2006, 19(1), 1-3.
[http://dx.doi.org/10.1097/01.wco.0000196155.92856.a1] [PMID: 16415670]
[11]
Choung, Y.H.; Park, K.; Shin, Y.R.; Cho, M.J. Intratympanic dexamethasone injection for refractory sudden sensorineural hearing loss. Laryngoscope, 2006, 116(5), 747-752.
[http://dx.doi.org/10.1097/01.mlg.0000205183.29986.f6] [PMID: 16652082]
[12]
Battista, R.A. Intratympanic dexamethasone for profound idiopathic sudden sensorineural hearing loss. Otolaryngol. Head Neck Surg., 2005, 132(6), 902-905.
[http://dx.doi.org/10.1016/j.otohns.2005.01.024] [PMID: 15944562]
[13]
Chandrasekhar, S.S. Intratympanic dexamethasone for sudden sensorineural hearing loss: Clinical and laboratory evaluation. Otol. Neurotol., 2001, 22(1), 18-23.
[http://dx.doi.org/10.1097/00129492-200101000-00005] [PMID: 11314710]
[14]
Haynes, D.S.; O’Malley, M.; Cohen, S.; Watford, K.; Labadie, R.F. Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy. Laryngoscope, 2007, 117(1), 3-15.
[http://dx.doi.org/10.1097/01.mlg.0000245058.11866.15] [PMID: 17202923]
[15]
Berjis, N.; Soheilipour, S.; Musavi, A.; Hashemi, S.M. Intratympanic dexamethasone injection vs. methylprednisolone for the treatment of refractory sudden sensorineural hearing loss. Adv. Biomed. Res., 2016, 5(1), 111.
[http://dx.doi.org/10.4103/2277-9175.184277] [PMID: 27403406]
[16]
Canlon, B.; Meltser, I.; Johansson, P.; Tahera, Y. Glucocorticoid receptors modulate auditory sensitivity to acoustic trauma. Hear. Res., 2007, 226(1-2), 61-69.
[http://dx.doi.org/10.1016/j.heares.2006.05.009] [PMID: 16843624]
[17]
Li, C.; Luo, Y.; Yang, C.; Yang, Y.; Luo, G. Study on the relationship between grα, grβ-isoform of glucocorticoid receptors and glucoeorticoid sensitivity in sudden sensorineural hearing loss. Chinese. Arch. Otolaryngol.-Head and Neck Surg., 2011, 5.
[18]
Zhang, X.; Chen, J.; Gao, Z.; Qi, H.; Dai, Y.; She, W. Response of glucocorticoid receptor alpha and histone deacetylase 2 to glucocorticoid treatment predicts the prognosis of sudden sensorineural hearing loss. Clin. Exp. Otorhinolaryngol., 2019, 12(4), 367-375.
[http://dx.doi.org/10.21053/ceo.2018.01298] [PMID: 30993958]
[19]
Haarman, E.G.; Kaspers, G.J.; Pieters, R.; Rottier, M.M.; Veerman, A.J. Glucocorticoid receptor alpha, beta and gamma expression vs. in vitro glucocorticod resistance in childhood leukemia. Leukemia, 2004, 18(3), 530-537.
[http://dx.doi.org/10.1038/sj.leu.2403225] [PMID: 14724649]
[20]
Gougat, C.; Jaffuel, D.; Gagliardo, R.; Henriquet, C.; Bousquet, J.; Demoly, P.; Mathieu, M. Overexpression of the human glucocorticoid receptor α and β isoforms inhibits AP-1 and NF-kappaB activities hormone independently. J. Mol. Med. (Berl.), 2002, 80(5), 309-318.
[http://dx.doi.org/10.1007/s00109-001-0302-6] [PMID: 12021843]
[21]
De Bosscher, K.; Beck, I.M.; Dejager, L.; Bougarne, N.; Gaigneaux, A.; Chateauvieux, S.; Ratman, D.; Bracke, M.; Tavernier, J.; Vanden Berghe, W.; Libert, C.; Diederich, M.; Haegeman, G. Selective modulation of the glucocorticoid receptor can distinguish between transrepression of NF-κB and AP-1. Cell. Mol. Life Sci., 2014, 71(1), 143-163.
[http://dx.doi.org/10.1007/s00018-013-1367-4] [PMID: 23784308]
[22]
Wagner, E.F.E.F. Bone development and inflammatory disease is regulated by AP-1 (Fos/Jun). Ann. Rheum. Dis., 2010, 69(Suppl. 1), i86-i88.
[http://dx.doi.org/10.1136/ard.2009.119396] [PMID: 19995753]
[23]
Wei, P.; Inamdar, N.; Vedeckis, W.V. Transrepression of c-jun gene expression by the glucocorticoid receptor requires both AP-1 sites in the c-Jun promoter. Mol. Endocrinol., 1998, 12(9), 1322-1333.
[http://dx.doi.org/10.1210/mend.12.9.0158] [PMID: 9731701]
[24]
Landegger, L.D.; Vasilijic, S.; Fujita, T.; Soares, V.Y.; Seist, R.; Xu, L.; Stankovic, K.M. Cytokine levels in inner ear fluid of young and aged mice as molecular biomarkers of noise-induced hearing loss. Front. Neurol., 2019, 10, 977.
[http://dx.doi.org/10.3389/fneur.2019.00977] [PMID: 31632328]
[25]
Mier, J.W. Immunotherapy with low-dose IL-2 in combination with GM-CSF. J. Immunother., 2003, 26(2), 95-96.
[http://dx.doi.org/10.1097/00002371-200303000-00001] [PMID: 12616100]
[26]
Yanhong, D.; Ling, L.; Qin, W.; Wenjie, Y.; Xiuling, Z.; Wandong, S. Preliminary study of the relationship of GR isoforms level of Peripheral Blood Mononuclear Cells (PBMCs) and prognosis in SSNHL patients. J. Audiol. Speech Pathol., 2013, 21(1), 32-36.
[27]
Xu, Q.; Leung, D.Y.; Kisich, K.O. Serine-arginine-rich protein p30 directs alternative splicing of glucocorticoid receptor pre-mRNA to glucocorticoid receptor beta in neutrophils. J. Biol. Chem., 2003, 278(29), 27112-27118.
[http://dx.doi.org/10.1074/jbc.M300824200] [PMID: 12738786]
[28]
Patel, G.C.; Liu, Y.; Millar, J.C.; Clark, A.F. Glucocorticoid receptor GRβ regulates glucocorticoid-induced ocular hypertension in mice. Sci. Rep., 2018, 8(1), 1-13.
[http://dx.doi.org/10.1038/s41598-018-19262-9] [PMID: 29311619]
[29]
Zhu, J.; Gong, J.Y.; Goodman, O.B., Jr; Cartegni, L.; Nanus, D.M.; Shen, R. Bombesin attenuates pre-mRNA splicing of glucocorticoid receptor by regulating the expression of serine-arginine protein p30c (SRp30c) in prostate cancer cells. Biochim. Biophys. Acta, 2007, 1773(7), 1087-1094.
[http://dx.doi.org/10.1016/j.bbamcr.2007.04.016] [PMID: 17540466]
[30]
Yu, H-H.; Seo, S-J.; Kim, Y-H.; Lee, H-Y.; Park, R-K.; So, H-S.; Jang, S.L.; You, Y.O. Protective effect of Rehmannia glutinosa on the cisplatin-induced damage of HEI-OC1 auditory cells through scavenging free radicals. J. Ethnopharmacol., 2006, 107(3), 383-388.
[http://dx.doi.org/10.1016/j.jep.2006.03.024] [PMID: 16698207]
[31]
Jeong, H-J.; Hong, S-H.; Park, R-K.; Shin, T.; An, N-H.; Kim, H-M. Hypoxia-induced IL-6 production is associated with activation of MAP kinase, HIF-1, and NF-kappaB on HEI-OC1 cells. Hear. Res., 2005, 207(1-2), 59-67.
[http://dx.doi.org/10.1016/j.heares.2005.04.003] [PMID: 15913932]
[32]
Vsevolodskaia, E.; Mironova, Z.; Ulitina, A.; Trofimov, V.; Pchelina, S.; Dubina, M. The role of histone deacetylase 2 (HDAC2) and Glucocorticoid Receptor (GR) isoforms α, β in patients with asthma-COPD overlap syndrome (ACOS). Eur. Respir. J., 2016, 48, PA879.
[33]
Dauphinee, S.M.; Karsan, A. Lipopolysaccharide signaling in endothelial cells. Lab. Invest., 2006, 86(1), 9-22.
[http://dx.doi.org/10.1038/labinvest.3700366] [PMID: 16357866]
[34]
Li, L.B.; Leung, D.Y.; Martin, R.J.; Goleva, E. Inhibition of histone deacetylase 2 expression by elevated glucocorticoid receptor β in steroid-resistant asthma. Am. J. Respir. Crit. Care Med., 2010, 182(7), 877-883.
[http://dx.doi.org/10.1164/rccm.201001-0015OC] [PMID: 20538962]
[35]
Coutinho, A.E.; Chapman, K.E. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol. Cell. Endocrinol., 2011, 335(1), 2-13.
[http://dx.doi.org/10.1016/j.mce.2010.04.005] [PMID: 20398732]
[36]
Alexiou, C.; Arnold, W.; Fauser, C.; Schratzenstaller, B.; Gloddek, B.; Fuhrmann, S.; Lamm, K. Sudden sensorineural hearing loss: Does application of glucocorticoids make sense? Arch. Otolaryngol. Head Neck Surg., 2001, 127(3), 253-258.
[http://dx.doi.org/10.1001/archotol.127.3.253] [PMID: 11255468]
[37]
Narozny, W.; Sicko, Z.; Przewozny, T.; Stankiewicz, C.; Kot, J.; Kuczkowski, J. Usefulness of high doses of glucocorticoids and hyperbaric oxygen therapy in sudden sensorineural hearing loss treatment. Otol. Neurotol., 2004, 25(6), 916-923.
[http://dx.doi.org/10.1097/00129492-200411000-00010] [PMID: 15547420]
[38]
Yukawa, H.; Shen, J.; Harada, N.; Cho-Tamaoka, H.; Yamashita, T. Acute effects of glucocorticoids on ATP-induced Ca2+ mobilization and nitric oxide production in cochlear spiral ganglion neurons. Neuroscience, 2005, 130(2), 485-496.
[http://dx.doi.org/10.1016/j.neuroscience.2004.09.037] [PMID: 15664705]
[39]
Smoak, K.A.; Cidlowski, J.A. Mechanisms of glucocorticoid receptor signaling during inflammation. Mech. Ageing Dev., 2004, 125(10-11), 697-706.
[http://dx.doi.org/10.1016/j.mad.2004.06.010] [PMID: 15541765]
[40]
Guo, Y.; Wu, Y.; Chen, W.; Lin, J. Endotoxic damage to the stria vascularis: The pathogenesis of sensorineural hearing loss secondary to otitis media? J. Laryngol. Otol., 1994, 108(4), 310-313.
[http://dx.doi.org/10.1017/S0022215100126623] [PMID: 8182316]
[41]
Zhou, Q-Q.; Dai, Y-H.; Du, X-P.; Hou, J.; Qi, H.; She, W-D. Aminophylline restores glucocorticoid sensitivity in a guinea pig model of sudden sensorineural hearing loss induced by lipopolysaccharide. Sci. Rep., 2017, 7(1), 2736.
[http://dx.doi.org/10.1038/s41598-017-02956-x] [PMID: 28578424]
[42]
Tanigawa, T.; Morikawa, A.; Hayashi, K.; Dan, K.; Tsuchihashi, N.; Goto, F.; Ueda, H.; Yokochi, T. Auditory cells produce nitric oxide in response to bacterial lipopolysaccharide. Innate Immun., 2013, 19(2), 115-120.
[http://dx.doi.org/10.1177/1753425912450347] [PMID: 22732735]
[43]
Freedman, N.D.; Yamamoto, K.R. Importin 7 and importin α/importin β are nuclear import receptors for the glucocorticoid receptor. Mol. Biol. Cell, 2004, 15(5), 2276-2286.
[http://dx.doi.org/10.1091/mbc.e03-11-0839] [PMID: 15004228]
[44]
Sousa, A.R.; Lane, S.J.; Cidlowski, J.A.; Staynov, D.Z.; Lee, T.H. Glucocorticoid resistance in asthma is associated with elevated in vivo expression of the glucocorticoid receptor β-isoform. J. Allergy Clin. Immunol., 2000, 105(5), 943-950.
[http://dx.doi.org/10.1067/mai.2000.106486] [PMID: 10808175]
[45]
Webster, J.C.; Oakley, R.H.; Jewell, C.M.; Cidlowski, J.A. Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative β isoform: a mechanism for the generation of glucocorticoid resistance. Proc. Natl. Acad. Sci. USA, 2001, 98(12), 6865-6870.
[http://dx.doi.org/10.1073/pnas.121455098] [PMID: 11381138]
[46]
Lewis-Tuffin, L.J.; Cidlowski, J.A. The physiology of human glucocorticoid receptor β (hGRbeta) and glucocorticoid resistance. Ann. N. Y. Acad. Sci., 2006, 1069(1), 1-9.
[http://dx.doi.org/10.1196/annals.1351.001] [PMID: 16855130]
[47]
Pipkin, M.E.; Sacks, J.A.; Cruz-Guilloty, F.; Lichtenheld, M.G.; Bevan, M.J.; Rao, A. Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity, 2010, 32(1), 79-90.
[http://dx.doi.org/10.1016/j.immuni.2009.11.012] [PMID: 20096607]
[48]
Salminen, A.; Huuskonen, J.; Ojala, J.; Kauppinen, A.; Kaarniranta, K.; Suuronen, T. Activation of innate immunity system during aging: NF-kB signaling is the molecular culprit of inflamm-aging. Ageing Res. Rev., 2008, 7(2), 83-105.
[http://dx.doi.org/10.1016/j.arr.2007.09.002] [PMID: 17964225]
[49]
Yamamoto, Y.; Gaynor, R.B. Role of the NF-kappaB pathway in the pathogenesis of human disease states. Curr. Mol. Med., 2001, 1(3), 287-296.
[http://dx.doi.org/10.2174/1566524013363816] [PMID: 11899077]
[50]
Liu, Y.; Yin, Y.; Zheng, L.; Zhang, R.; Zong, D. Zou, J. HU, L. Y., Effects of SRSF9/SRp30c on proliferation and migration abilities of glio-ma cells by regulating GRβ. Chinese J. Pathophysiol., 2017, 33(10), 1825-1830.
[51]
Oh, G-S.; Kim, H-J.; Choi, J-H.; Shen, A.; Kim, C-H.; Kim, S-J.; Shin, S-R.; Hong, S-H.; Kim, Y.; Park, C.; Lee, S.J.; Akira, S.; Park, R.; So, H.S. Activation of lipopolysaccharide-TLR4 signaling accelerates the ototoxic potential of cisplatin in mice. J. Immunol., 2011, 186(2), 1140-1150.
[http://dx.doi.org/10.4049/jimmunol.1002183] [PMID: 21148032]